Integrated DNA Technologies Partners with Illumina to Launch New Analysis Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. By connecting IDT's library prep with Illumina's DRAGEN secondary analysis platform, researchers can reduce downstream burden and accelerate the path from sequencing to insight with greater speed and consistency. IDT's xGen FFPE and cfDNA workflows already support hundreds of thousands of samples annually, and this collaboration is designed to reduce the NGS analysis burden by streamlining the journey from sample to insights for oncology researchers. The DRAGEN Somatic for IDT Custom Panels was designed for use with IDT library prep workflows and optimized for challenging FFPE samples with a new, low-quality FFPE mode. This integrated workflow ensures that researchers can collect more reliable insights from degraded oncology research samples.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 182.670
Low
240.00
Averages
266.18
High
310.00
Current: 182.670
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SCIEX Unveils New Features for ZenoTOF Series
- Software Upgrade: The introduction of SCIEX OS 5.0 software with features like Central Metrics Tracker and AI-enabled help functions allows researchers to tackle complex biological questions more efficiently, thereby enhancing workflow simplification and data insight capabilities.
- Technological Innovation: The ZenoTOF 8600 system has demonstrated 10% to 40% gains in identification and quantitation for low-input proteomics workflows, enhancing sensitivity for high-throughput screening and accelerating early discovery processes.
- Enhanced Front-End Compatibility: Integration with the Echo® MS+ system positions the ZenoTOF 8600 as the industry's highest-throughput accurate mass platform, sampling at one sample per second, significantly reducing complexity and consumable costs.
- Collaboration Expansion: The agreement between SCIEX and IonOpticks aims to provide advanced liquid chromatography solutions for the proteomics community, further integrating high sensitivity and throughput analyses, enabling researchers to gain deeper insights within their existing workflows.
See More
SCIEX Launches Next-Gen V55 Mass Spectrometer for High-Pressure Labs
- Performance Enhancement: The newly launched novus V55 system significantly surpasses the SCIEX 5500+ in sensitivity and output speed, capable of acquiring up to 1,000 MRMs per second, greatly increasing sample throughput and expanding testing capabilities to meet high-pressure labs' demands for rapid results.
- Energy-Efficient Design: The system achieves a 40% reduction in energy consumption and laboratory cooling requirements, helping customers lower operational costs and demonstrating SCIEX's commitment to sustainability.
- Compact Footprint: With a 35% smaller footprint than competitors, the V55 optimizes laboratory space utilization without compromising sensitivity or quantitative performance, addressing modern labs' stringent space requirements.
- Software Innovation: The new SCIEX OS 5.0 software introduces Central Metrics Tracker and AI-enabled features, enhancing user experience and report generation efficiency, allowing labs to manage and analyze data more effectively.
See More
Wall Street Rises with Strong Tech Stock Performance
- Strong Market Rally: Futures indicate an up day for Wall Street as the S&P 500 and Nasdaq hit record highs, driven by AI-related stocks like Micron, which surged 19% and surpassed a $1 trillion market cap, reflecting robust demand for AI chips.
- Micron's Continued Ascent: Micron's stock rose another 7% in premarket trading, achieving a remarkable increase from $500 billion to $1 trillion in just 48 days, the fastest on record, highlighting the ongoing shortage and insatiable demand for memory chips, suggesting significant future growth potential.
- SK Hynix Joins the $1 Trillion Club: South Korean memory giant SK Hynix also crossed the $1 trillion market cap threshold in today's trading, underscoring the strong growth in the global memory market and the increasing demand driven by the AI era.
- Upgrades for FedEx and Danaher: JPMorgan upgraded FedEx from hold to buy with a price target raised to $460, citing attractive risk/reward ahead of its freight unit separation; meanwhile, Citi reinstated Danaher with a buy rating and a $230 price target, reflecting optimism in the bioprocessing sector.
See More
Henry Schein Appoints New Board Chairman
- New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
- Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
- Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
- Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
See More
Danaher Anticipates 6% Revenue Growth by 2027
- Revenue Growth Outlook: Danaher anticipates approximately 6% revenue growth by 2027, primarily driven by a rebound in bioprocess demand, indicating the company's market potential and signs of recovery in the biotech sector.
- Market Demand Recovery: As the bioprocessing industry rebounds, demand for Danaher's products and services is expected to increase, providing new revenue streams and enhancing its competitive position in the market.
- Strategic Adjustments: The company may adjust its product portfolio in response to changing market demands, thereby improving overall business performance and profitability to better meet customer needs.
- Long-Term Perspective: This growth outlook reflects Danaher's confidence in future markets, suggesting that the company's investments and innovations in biotechnology will continue to drive sustainable development.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
SCIEX Unveils New Features for ZenoTOF Series
- Software Upgrade: The introduction of SCIEX OS 5.0 software with features like Central Metrics Tracker and AI-enabled help functions allows researchers to tackle complex biological questions more efficiently, thereby enhancing workflow simplification and data insight capabilities.
- Technological Innovation: The ZenoTOF 8600 system has demonstrated 10% to 40% gains in identification and quantitation for low-input proteomics workflows, enhancing sensitivity for high-throughput screening and accelerating early discovery processes.
- Enhanced Front-End Compatibility: Integration with the Echo® MS+ system positions the ZenoTOF 8600 as the industry's highest-throughput accurate mass platform, sampling at one sample per second, significantly reducing complexity and consumable costs.
- Collaboration Expansion: The agreement between SCIEX and IonOpticks aims to provide advanced liquid chromatography solutions for the proteomics community, further integrating high sensitivity and throughput analyses, enabling researchers to gain deeper insights within their existing workflows.
See More
SCIEX Launches Next-Gen V55 Mass Spectrometer for High-Pressure Labs
- Performance Enhancement: The newly launched novus V55 system significantly surpasses the SCIEX 5500+ in sensitivity and output speed, capable of acquiring up to 1,000 MRMs per second, greatly increasing sample throughput and expanding testing capabilities to meet high-pressure labs' demands for rapid results.
- Energy-Efficient Design: The system achieves a 40% reduction in energy consumption and laboratory cooling requirements, helping customers lower operational costs and demonstrating SCIEX's commitment to sustainability.
- Compact Footprint: With a 35% smaller footprint than competitors, the V55 optimizes laboratory space utilization without compromising sensitivity or quantitative performance, addressing modern labs' stringent space requirements.
- Software Innovation: The new SCIEX OS 5.0 software introduces Central Metrics Tracker and AI-enabled features, enhancing user experience and report generation efficiency, allowing labs to manage and analyze data more effectively.
See More
Wall Street Rises with Strong Tech Stock Performance
- Strong Market Rally: Futures indicate an up day for Wall Street as the S&P 500 and Nasdaq hit record highs, driven by AI-related stocks like Micron, which surged 19% and surpassed a $1 trillion market cap, reflecting robust demand for AI chips.
- Micron's Continued Ascent: Micron's stock rose another 7% in premarket trading, achieving a remarkable increase from $500 billion to $1 trillion in just 48 days, the fastest on record, highlighting the ongoing shortage and insatiable demand for memory chips, suggesting significant future growth potential.
- SK Hynix Joins the $1 Trillion Club: South Korean memory giant SK Hynix also crossed the $1 trillion market cap threshold in today's trading, underscoring the strong growth in the global memory market and the increasing demand driven by the AI era.
- Upgrades for FedEx and Danaher: JPMorgan upgraded FedEx from hold to buy with a price target raised to $460, citing attractive risk/reward ahead of its freight unit separation; meanwhile, Citi reinstated Danaher with a buy rating and a $230 price target, reflecting optimism in the bioprocessing sector.
See More
Henry Schein Appoints New Board Chairman
- New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
- Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
- Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
- Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
See More
Danaher Anticipates 6% Revenue Growth by 2027
- Revenue Growth Outlook: Danaher anticipates approximately 6% revenue growth by 2027, primarily driven by a rebound in bioprocess demand, indicating the company's market potential and signs of recovery in the biotech sector.
- Market Demand Recovery: As the bioprocessing industry rebounds, demand for Danaher's products and services is expected to increase, providing new revenue streams and enhancing its competitive position in the market.
- Strategic Adjustments: The company may adjust its product portfolio in response to changing market demands, thereby improving overall business performance and profitability to better meet customer needs.
- Long-Term Perspective: This growth outlook reflects Danaher's confidence in future markets, suggesting that the company's investments and innovations in biotechnology will continue to drive sustainable development.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
